Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: Metab Brain Dis. 2013 May 3;28(3):375–386. doi: 10.1007/s11011-013-9413-3

Figure 1. Adoptive transfer of IL-10-GFP+ B-cells to µMT−/− mice reduces ischemic infarct size and experimental stroke outcome.

Figure 1

A. Schematic representation of enrichment of IL-10+ GFP+ CD19+ B-cells from spleens of IL-10 GFP reporter mice, cultured in the presence of 1µg/ml LPS for 48 hours and adoptive transfer of 5 million IL-10-GFP+ B-cells into µMT−/− mice, via i.v. injections. B. Intravenous transfer of 5 million IL-10-GFP+ B-cells reduced infarct volume in µMT−/− B-cell deficient mice 48 hours following 60 minutes of middle cerebral artery occlusion (MCAO) compared to intravenous transfer of RPMI vehicle (no cells). *p≤0.05; **p≤0.01 (Student t-test). C. Representative 2,3,5 triphenyltetetrazolium chloride stained cerebral sections 48 hours following 60 minutes of MCAO. Localization of the ischemic lesion differed between µMT−/− mice receiving intravenous IL-10-GFP+ B-cells or RPMI vehicle (no cells). D. Purified B-cells obtained from IL-10 GFP reporter mice were further characterized for regulatory B-cell sub-populations (B10, B1a & T2-MZ) after 48 hours of culture in the presence of LPS by flow cytometry.